{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:49:00Z","timestamp":1792097340318,"version":"4.4.0"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T00:00:00Z","timestamp":1787961600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-026-03374-8","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T06:51:25Z","timestamp":1787986285000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting the PI3K\/AKT\/mTOR pathway in gastrointestinal cancers: a comprehensive review of mechanisms, preclinical evidence, and clinical challenges"],"prefix":"10.1007","volume":"43","author":[{"given":"Faride","family":"Kaikavoosnejad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Haddad Kashani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khadijeh","family":"Dizaji Asl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeinab","family":"Mazloumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Keyhani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyyede Sepide","family":"Ashraf Moosavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milad","family":"Verdi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5594-2906","authenticated-orcid":false,"given":"Ali","family":"Rafat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,29]]},"reference":[{"issue":"1","key":"3374_CR1","first-page":"4346576","volume":"2017","author":"L Procaccio","year":"2017","unstructured":"Procaccio L, Schirripa M, Fassan M, Vecchione L, Bergamo F, Prete AA, et al. Immunotherapy in gastrointestinal cancers. Biomed Res Int. 2017;2017(1):4346576.","journal-title":"Biomed Res Int"},{"issue":"4","key":"3374_CR2","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/jn\/nxz268","volume":"150","author":"SK Clinton","year":"2020","unstructured":"Clinton SK, Giovannucci EL, Hursting SD. The world cancer research fund\/American institute for cancer research third expert report on diet, nutrition, physical activity, and cancer: impact and future directions. J Nutr. 2020;150(4):663\u201371.","journal-title":"J Nutr"},{"issue":"5","key":"3374_CR3","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41571-023-00747-0","volume":"20","author":"AP Thrift","year":"2023","unstructured":"Thrift AP, Wenker TN, El-Serag HB. Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention. Nat reviews Clin Oncol. 2023;20(5):338\u201349.","journal-title":"Nat reviews Clin Oncol"},{"issue":"2","key":"3374_CR4","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1136\/gutjnl-2022-327736","volume":"72","author":"E Morgan","year":"2023","unstructured":"Morgan E, Arnold M, Gini A, Lorenzoni V, Cabasag CJ, Laversanne M, et al. Global burden of colorectal cancer in 2020 and 2040: incidence and mortality estimates from GLOBOCAN. Gut. 2023;72(2):338\u201344.","journal-title":"Gut"},{"issue":"3","key":"3374_CR5","first-page":"236","volume":"19","author":"A Singh","year":"2024","unstructured":"Singh A. Global burden of five major types of gastrointestinal cancer. Gastroenterol Review\/Przegl\u0105d Gastroenterologiczny. 2024;19(3):236\u201354.","journal-title":"Gastroenterol Review\/Przegl\u0105d Gastroenterologiczny"},{"issue":"20","key":"3374_CR6","doi-asserted-by":"crossref","first-page":"2514","DOI":"10.3748\/wjg.v26.i20.2514","volume":"26","author":"G Nannini","year":"2020","unstructured":"Nannini G, Meoni G, Amedei A, Tenori L. Metabolomics profile in gastrointestinal cancers: Update and future perspectives. World J Gastroenterol. 2020;26(20):2514.","journal-title":"World J Gastroenterol"},{"issue":"2","key":"3374_CR7","doi-asserted-by":"crossref","first-page":"e43809","DOI":"10.34172\/ipp.2025.43809","volume":"11","author":"M Safaei","year":"2025","unstructured":"Safaei M, Mortezaei NT, Azmoudeh-Ardalan F, Jafarian A, Niyari EE, Bouzari B. The role of clinicopathological features in the prognosis of resected pancreatic ductal adenocarcinoma: a retrospective study. Immunopathol Persa. 2025;11(2):e43809\u2013e.","journal-title":"Immunopathol Persa"},{"issue":"1","key":"3374_CR8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3390\/pharmaceutics13010103","volume":"13","author":"AG Quiroz-Reyes","year":"2021","unstructured":"Quiroz-Reyes AG, Islas JF, Delgado-Gonzalez P, Franco-Villarreal H, Garza-Trevi\u00f1o EN. Therapeutic approaches for metastases from colorectal cancer and pancreatic ductal carcinoma. Pharmaceutics. 2021;13(1):103.","journal-title":"Pharmaceutics"},{"issue":"3","key":"3374_CR9","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.3390\/cancers6031441","volume":"6","author":"T Matsuoka","year":"2014","unstructured":"Matsuoka T, Yashiro M. The Role of PI3K\/Akt\/mTOR Signaling in Gastric Carcinoma. Cancers (Basel). 2014;6(3):1441\u201363.","journal-title":"Cancers (Basel)"},{"issue":"11","key":"3374_CR10","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/nrclinonc.2013.170","volume":"10","author":"R Wadhwa","year":"2013","unstructured":"Wadhwa R, Song S, Lee JS, Yao Y, Wei Q, Ajani JA. Gastric cancer-molecular and clinical dimensions. Nat Rev Clin Oncol. 2013;10(11):643\u201355.","journal-title":"Nat Rev Clin Oncol"},{"key":"3374_CR11","doi-asserted-by":"crossref","unstructured":"Bang J, Jun M, Lee S, Moon H, Ro SW. Targeting EGFR\/PI3K\/AKT\/mTOR signaling in hepatocellular carcinoma. Pharmaceutics. 2023;15(8):2130.","DOI":"10.3390\/pharmaceutics15082130"},{"key":"3374_CR12","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1146\/annurev-med-062913-051343","volume":"67","author":"IA Mayer","year":"2016","unstructured":"Mayer IA, Arteaga CL. The PI3K\/AKT Pathway as a Target for Cancer Treatment. Annu Rev Med. 2016;67:11\u201328.","journal-title":"Annu Rev Med"},{"key":"3374_CR13","doi-asserted-by":"crossref","unstructured":"Leiphrakpam PD, Are C. PI3K\/Akt\/mTOR signaling pathway as a target for colorectal cancer treatment. Int J Mol Sci. 2024;25(6):3178.","DOI":"10.3390\/ijms25063178"},{"issue":"3","key":"3374_CR14","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1200\/JCO.2011.36.1360","volume":"30","author":"JC Bendell","year":"2012","unstructured":"Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, et al. Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2012;30(3):282\u201390.","journal-title":"J Clin Oncol"},{"issue":"9","key":"3374_CR15","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1001\/jamaoncol.2019.0034","volume":"5","author":"A Esposito","year":"2019","unstructured":"Esposito A, Viale G, Curigliano G. Safety, Tolerability, and Management of Toxic Effects of Phosphatidylinositol 3-Kinase Inhibitor Treatment in Patients With Cancer: A Review. JAMA Oncol. 2019;5(9):1347\u201354.","journal-title":"JAMA Oncol"},{"issue":"1","key":"3374_CR16","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.apsb.2021.07.023","volume":"12","author":"J Wang","year":"2022","unstructured":"Wang J, Hu K, Cai X, Yang B, He Q, Wang J, et al. Targeting PI3K\/AKT signaling for treatment of idiopathic pulmonary fibrosis. Acta Pharm Sin B. 2022;12(1):18\u201332.","journal-title":"Acta Pharm Sin B"},{"issue":"1","key":"3374_CR17","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.apsb.2021.07.023","volume":"12","author":"J Wang","year":"2022","unstructured":"Wang J, Hu K, Cai X, Yang B, He Q, Wang J, et al. Targeting PI3K\/AKT signaling for treatment of idiopathic pulmonary fibrosis. Acta Pharm Sinica B. 2022;12(1):18\u201332.","journal-title":"Acta Pharm Sinica B"},{"key":"3374_CR18","doi-asserted-by":"crossref","first-page":"107300","DOI":"10.1016\/j.phrs.2024.107300","volume":"206","author":"N Guo","year":"2024","unstructured":"Guo N, Wang X, Xu M, Bai J, Yu H, Zhang L. PI3K\/AKT signaling pathway: molecular mechanisms and therapeutic potential in depression. Pharmacol Res. 2024;206:107300.","journal-title":"Pharmacol Res"},{"issue":"12","key":"3374_CR19","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1007\/s11912-019-0846-7","volume":"21","author":"H Ellis","year":"2019","unstructured":"Ellis H, Ma CX. PI3K inhibitors in breast cancer therapy. Curr Oncol Rep. 2019;21(12):110.","journal-title":"Curr Oncol Rep"},{"issue":"1","key":"3374_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/nrc3860","volume":"15","author":"LM Thorpe","year":"2015","unstructured":"Thorpe LM, Yuzugullu H, Zhao JJ. PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting. Nat Rev Cancer. 2015;15(1):7\u201324.","journal-title":"Nat Rev Cancer"},{"issue":"6","key":"3374_CR21","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41419-020-2631-9","volume":"11","author":"F Liu","year":"2020","unstructured":"Liu F, Wu X, Qian Y, Jiang X, Wang Y, Gao J. PIK3C3 regulates the expansion of liver CSCs and PIK3C3 inhibition counteracts liver cancer stem cell activity induced by PI3K inhibitor. Cell Death Dis. 2020;11(6):427.","journal-title":"Cell Death Dis"},{"issue":"3","key":"3374_CR22","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s12640-019-0003-y","volume":"35","author":"SN Rai","year":"2019","unstructured":"Rai SN, Dilnashin H, Birla H, Singh SS, Zahra W, Rathore AS, et al. The role of PI3K\/Akt and ERK in neurodegenerative disorders. Neurotox Res. 2019;35(3):775\u201395.","journal-title":"Neurotox Res"},{"issue":"1","key":"3374_CR23","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3390\/ijms22010173","volume":"22","author":"D Miricescu","year":"2020","unstructured":"Miricescu D, Totan A, Stanescu-Spinu I-I, Badoiu SC, Stefani C, Greabu M. PI3K\/AKT\/mTOR signaling pathway in breast cancer: from molecular landscape to clinical aspects. Int J Mol Sci. 2020;22(1):173.","journal-title":"Int J Mol Sci"},{"key":"3374_CR24","doi-asserted-by":"crossref","first-page":"819128","DOI":"10.3389\/fonc.2022.819128","volume":"12","author":"Y Peng","year":"2022","unstructured":"Peng Y, Wang Y, Zhou C, Mei W, Zeng C. PI3K\/Akt\/mTOR pathway and its role in cancer therapeutics: are we making headway? Front Oncol. 2022;12:819128.","journal-title":"Front Oncol"},{"issue":"7396","key":"3374_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/nature10912","volume":"485","author":"AC Hsieh","year":"2012","unstructured":"Hsieh AC, Liu Y, Edlind MP, Ingolia NT, Janes MR, Sher A, et al. The translational landscape of mTOR signalling steers cancer initiation and metastasis. Nature. 2012;485(7396):55\u201361.","journal-title":"Nature"},{"key":"3374_CR26","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ejca.2017.06.003","volume":"83","author":"N Golob-Schwarzl","year":"2017","unstructured":"Golob-Schwarzl N, Krassnig S, Toeglhofer AM, Park YN, Gogg-Kamerer M, Vierlinger K, et al. New liver cancer biomarkers: PI3K\/AKT\/mTOR pathway members and eukaryotic translation initiation factors. Eur J Cancer. 2017;83:56\u201370.","journal-title":"Eur J Cancer"},{"issue":"1","key":"3374_CR27","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","volume":"22","author":"A Glaviano","year":"2023","unstructured":"Glaviano A, Foo ASC, Lam HY, Yap KCH, Jacot W, Jones RH, et al. PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer. Mol Cancer. 2023;22(1):138.","journal-title":"Mol Cancer"},{"key":"3374_CR28","doi-asserted-by":"crossref","unstructured":"Riquelme I, P\u00e9rez-Moreno P, Mora-Lagos B, Ili C, Brebi P, Roa JC. Long non-coding RNAs (lncRNAs) as regulators of the PI3K\/AKT\/mTOR Pathway in gastric carcinoma. Int J Mol Sci. 2023;24(7):6294.","DOI":"10.3390\/ijms24076294"},{"issue":"9","key":"3374_CR29","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.tcb.2015.06.002","volume":"25","author":"CC Dibble","year":"2015","unstructured":"Dibble CC, Cantley LC. Regulation of mTORC1 by PI3K signaling. Trends Cell Biol. 2015;25(9):545\u201355.","journal-title":"Trends Cell Biol"},{"key":"3374_CR30","doi-asserted-by":"crossref","first-page":"173983","DOI":"10.1016\/j.ejphar.2021.173983","volume":"898","author":"ABS Khorasani","year":"2021","unstructured":"Khorasani ABS, Pourbagheri-Sigaroodi A, Pirsalehi A, Safaroghli-Azar A, Zali MR, Bashash D. The PI3K\/Akt\/mTOR signaling pathway in gastric cancer; from oncogenic variations to the possibilities for pharmacologic interventions. Eur J Pharmacol. 2021;898:173983.","journal-title":"Eur J Pharmacol"},{"issue":"5670","key":"3374_CR31","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1126\/science.1096502","volume":"304","author":"Y Samuels","year":"2004","unstructured":"Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science. 2004;304(5670):554.","journal-title":"Science"},{"issue":"11","key":"3374_CR32","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.ejca.2005.04.022","volume":"41","author":"S Velho","year":"2005","unstructured":"Velho S, Oliveira C, Ferreira A, Ferreira AC, Suriano G, Schwartz S Jr, et al. The prevalence of PIK3CA mutations in gastric and colon cancer. Eur J Cancer. 2005;41(11):1649\u201354.","journal-title":"Eur J Cancer"},{"issue":"1","key":"3374_CR33","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1038\/s41467-017-02002-4","volume":"8","author":"IM Berenjeno","year":"2017","unstructured":"Berenjeno IM, Pi\u00f1eiro R, Castillo SD, Pearce W, McGranahan N, Dewhurst SM, et al. Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling. Nat Commun. 2017;8(1):1773.","journal-title":"Nat Commun"},{"issue":"1","key":"3374_CR34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/s13027-018-0216-3","volume":"13","author":"FF Munari","year":"2018","unstructured":"Munari FF, Cruvinel-Carloni A, Lacerda CF, De Oliveira ATT, Scapulatempo-Neto C, Da Silva SRM, et al. PIK3CA mutations are frequent in esophageal squamous cell carcinoma associated with chagasic megaesophagus and are associated with a worse patient outcome. Infect Agents Cancer. 2018;13(1):43.","journal-title":"Infect Agents Cancer"},{"issue":"1","key":"3374_CR35","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1159\/000356201","volume":"89","author":"Y Sukawa","year":"2014","unstructured":"Sukawa Y, Yamamoto H, Nosho K, Ito M, Igarashi H, Naito T, et al. HER2 expression and PI3K-Akt pathway alterations in gastric cancer. Digestion. 2014;89(1):12\u20137.","journal-title":"Digestion"},{"issue":"45","key":"3374_CR36","doi-asserted-by":"crossref","first-page":"6577","DOI":"10.3748\/wjg.v18.i45.6577","volume":"18","author":"Y Sukawa","year":"2012","unstructured":"Sukawa Y, Yamamoto H, Nosho K, Kunimoto H, Suzuki H, Adachi Y, et al. Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-Akt pathway in gastric cancer. World J Gastroenterology: WJG. 2012;18(45):6577.","journal-title":"World J Gastroenterology: WJG"},{"issue":"3","key":"3374_CR37","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ejca.2010.09.008","volume":"47","author":"G Corso","year":"2011","unstructured":"Corso G, Velho S, Paredes J, Pedrazzani C, Martins D, Milanezi F, et al. Oncogenic mutations in gastric cancer with microsatellite instability. Eur J Cancer. 2011;47(3):443\u201351.","journal-title":"Eur J Cancer"},{"issue":"6","key":"3374_CR38","doi-asserted-by":"crossref","first-page":"8201","DOI":"10.3892\/mmr.2015.4424","volume":"12","author":"D Li","year":"2015","unstructured":"Li D, Xu CY, Cui RJ, Tang JB, Sun H, Yang ZK, et al. DNA methylation inhibitor, decitabine, promotes MGC803 gastric cancer cell migration and invasion via the upregulation of NEDD4\u20131. Mol Med Rep. 2015;12(6):8201\u20138.","journal-title":"Mol Med Rep"},{"issue":"4","key":"3374_CR39","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1007\/s12079-016-0327-9","volume":"10","author":"AA Samadani","year":"2016","unstructured":"Samadani AA, Nikbakhsh N, Pilehchian M, Fattahi S, Akhavan-Niaki H. Epigenetic changes of CDX2 in gastric adenocarcinoma. J Cell Commun Signal. 2016;10(4):267\u201372.","journal-title":"J Cell Commun Signal"},{"issue":"4","key":"3374_CR40","doi-asserted-by":"crossref","first-page":"4115","DOI":"10.1002\/jcp.27220","volume":"234","author":"E Ghadami","year":"2019","unstructured":"Ghadami E, Nikbakhsh N, Fattahi S, Kosari-Monfared M, Ranaee M, Taheri H, et al. Epigenetic alterations of CYLD promoter modulate its expression in gastric adenocarcinoma: A footprint of infections. J Cell Physiol. 2019;234(4):4115\u201324.","journal-title":"J Cell Physiol"},{"key":"3374_CR41","doi-asserted-by":"crossref","first-page":"118513","DOI":"10.1016\/j.lfs.2020.118513","volume":"262","author":"S Fattahi","year":"2020","unstructured":"Fattahi S, Amjadi-Moheb F, Tabaripour R, Ashrafi GH, Akhavan-Niaki H. PI3K\/AKT\/mTOR signaling in gastric cancer: Epigenetics and beyond. Life Sci. 2020;262:118513.","journal-title":"Life Sci"},{"issue":"2","key":"3374_CR42","doi-asserted-by":"crossref","first-page":"e43928","DOI":"10.34172\/ipp.2025.43928","volume":"12","author":"SA Azimi","year":"2025","unstructured":"Azimi SA, Farzadifar E, Pasdar A, Amerizadeh F. Network-based analysis of microRNAs targeting the RAS\/MAPK signaling pathway in colorectal cancer. Immunopathol Persa. 2025;12(2):e43928\u2013e.","journal-title":"Immunopathol Persa"},{"key":"3374_CR43","doi-asserted-by":"crossref","first-page":"173983","DOI":"10.1016\/j.ejphar.2021.173983","volume":"898","author":"A Baghery Saghchy Khorasani","year":"2021","unstructured":"Baghery Saghchy Khorasani A, Pourbagheri-Sigaroodi A, Pirsalehi A, Safaroghli-Azar A, Zali MR, Bashash D. The PI3K\/Akt\/mTOR signaling pathway in gastric cancer; from oncogenic variations to the possibilities for pharmacologic interventions. Eur J Pharmacol. 2021;898:173983.","journal-title":"Eur J Pharmacol"},{"issue":"4","key":"3374_CR44","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1111\/j.1582-4934.2005.tb00379.x","volume":"9","author":"AM Byrne","year":"2005","unstructured":"Byrne AM, Bouchier-Hayes DJ, Harmey JH. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med. 2005;9(4):777\u201394.","journal-title":"J Cell Mol Med"},{"issue":"15","key":"3374_CR45","first-page":"5911","volume":"61","author":"G Dong","year":"2001","unstructured":"Dong G, Chen Z, Li ZY, Yeh NT, Bancroft CC, Van Waes C. Hepatocyte growth factor\/scatter factor-induced activation of MEK and PI3K signal pathways contributes to expression of proangiogenic cytokines interleukin-8 and vascular endothelial growth factor in head and neck squamous cell carcinoma. Cancer Res. 2001;61(15):5911\u20138.","journal-title":"Cancer Res"},{"issue":"1","key":"3374_CR46","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2174\/156800908783497122","volume":"8","author":"BH Jiang","year":"2008","unstructured":"Jiang BH, Liu LZ. AKT signaling in regulating angiogenesis. Curr Cancer Drug Targets. 2008;8(1):19\u201326.","journal-title":"Curr Cancer Drug Targets"},{"issue":"4","key":"3374_CR47","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1073\/pnas.040560897","volume":"97","author":"BH Jiang","year":"2000","unstructured":"Jiang BH, Zheng JZ, Aoki M, Vogt PK. Phosphatidylinositol 3-kinase signaling mediates angiogenesis and expression of vascular endothelial growth factor in endothelial cells. Proc Natl Acad Sci U S A. 2000;97(4):1749\u201353.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"3374_CR48","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s12282-024-01567-5","volume":"31","author":"HP Zhang","year":"2024","unstructured":"Zhang HP, Jiang RY, Zhu JY, Sun KN, Huang Y, Zhou HH, et al. PI3K\/AKT\/mTOR signaling pathway: an important driver and therapeutic target in triple-negative breast cancer. Breast Cancer. 2024;31(4):539\u201351.","journal-title":"Breast Cancer"},{"issue":"7","key":"3374_CR49","doi-asserted-by":"publisher","first-page":"e13502","DOI":"10.15252\/emmm.202013502","volume":"13","author":"B Thibault","year":"2021","unstructured":"Thibault B, Ramos-Delgado F, Pons-Tostivint E, Therville N, Cintas C, Arcucci S, et al. Pancreatic cancer intrinsic PI3K\u03b1 activity accelerates metastasis and rewires macrophage component. EMBO Mol Med. 2021;13(7):e13502.","journal-title":"EMBO Mol Med"},{"key":"3374_CR50","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.biopha.2018.04.072","volume":"103","author":"J Yang","year":"2018","unstructured":"Yang J, Pi C, Wang G. Inhibition of PI3K\/Akt\/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells. Biomed Pharmacother. 2018;103:699\u2013707.","journal-title":"Biomed Pharmacother"},{"issue":"10","key":"3374_CR51","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.4251\/wjgo.v15.i10.1739","volume":"15","author":"L Yang","year":"2023","unstructured":"Yang L, Liu YN, Gu Y, Guo Q. Deltonin enhances gastric carcinoma cell apoptosis and chemosensitivity to cisplatin via inhibiting PI3K\/AKT\/mTOR and MAPK signaling. World J Gastrointest Oncol. 2023;15(10):1739\u201355.","journal-title":"World J Gastrointest Oncol"},{"issue":"3","key":"3374_CR52","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1002\/jcb.23405","volume":"113","author":"N Awasthi","year":"2012","unstructured":"Awasthi N, Yen PL, Schwarz MA, Schwarz RE. The efficacy of a novel, dual PI3K\/mTOR inhibitor NVP-BEZ235 to enhance chemotherapy and antiangiogenic response in pancreatic cancer. J Cell Biochem. 2012;113(3):784\u201391.","journal-title":"J Cell Biochem"},{"issue":"9","key":"3374_CR53","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1016\/j.bcp.2012.08.007","volume":"84","author":"BN Singh","year":"2012","unstructured":"Singh BN, Kumar D, Shankar S, Srivastava RK. Rottlerin induces autophagy which leads to apoptotic cell death through inhibition of PI3K\/Akt\/mTOR pathway in human pancreatic cancer stem cells. Biochem Pharmacol. 2012;84(9):1154\u201363.","journal-title":"Biochem Pharmacol"},{"issue":"7","key":"3374_CR54","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/j.1582-4934.2008.00364.x","volume":"13","author":"H Huynh","year":"2009","unstructured":"Huynh H, Chow KH, Soo KC, Toh HC, Choo SP, Foo KF, et al. RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma. J Cell Mol Med. 2009;13(7):1371\u201380.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"3374_CR55","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3892\/ijo.2020.5151","volume":"58","author":"J Wang","year":"2021","unstructured":"Wang J, Liang D, Zhang XP, He CF, Cao L, Zhang SQ, et al. Novel PI3K\/Akt\/mTOR signaling inhibitor, W922, prevents colorectal cancer growth via the regulation of autophagy. Int J Oncol. 2021;58(1):70\u201382.","journal-title":"Int J Oncol"},{"issue":"11","key":"3374_CR56","doi-asserted-by":"crossref","first-page":"e113037","DOI":"10.1371\/journal.pone.0113037","volume":"9","author":"TM Pitts","year":"2014","unstructured":"Pitts TM, Newton TP, Bradshaw-Pierce EL, Addison R, Arcaroli JJ, Klauck PJ, et al. Dual pharmacological targeting of the MAP kinase and PI3K\/mTOR pathway in preclinical models of colorectal cancer. PLoS ONE. 2014;9(11):e113037.","journal-title":"PLoS ONE"},{"key":"3374_CR57","doi-asserted-by":"crossref","first-page":"100936","DOI":"10.1016\/j.neo.2023.100936","volume":"45","author":"K Wang","year":"2023","unstructured":"Wang K, Tang J, Fan S, Su H, Yu R, Zhang Y, et al. ABBV-744 induces autophagy in gastric cancer cells by regulating PI3K\/AKT\/mTOR\/p70S6k and MAPK signaling pathways. Neoplasia. 2023;45:100936.","journal-title":"Neoplasia"},{"key":"3374_CR58","first-page":"1293","volume":"9","author":"CX Yuan","year":"2015","unstructured":"Yuan CX, Zhou ZW, Yang YX, He ZX, Zhang X, Wang D, et al. Danusertib, a potent pan-Aurora kinase and ABL kinase inhibitor, induces cell cycle arrest and programmed cell death and inhibits epithelial to mesenchymal transition involving the PI3K\/Akt\/mTOR-mediated signaling pathway in human gastric cancer AGS and NCI-N78 cells. Drug Des Devel Ther. 2015;9:1293\u2013318.","journal-title":"Drug Des Devel Ther"},{"key":"3374_CR59","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.2147\/OTT.S172957","volume":"11","author":"L Li","year":"2018","unstructured":"Li L, Zhang S, Xie D, Chen H, Zheng X, Pan D. Dual inhibitor of PI3K and mTOR (NVP-BEZ235) augments the efficacy of fluorouracil on gastric cancer chemotherapy. Onco Targets Ther. 2018;11:6111\u20138.","journal-title":"Onco Targets Ther"},{"issue":"2","key":"3374_CR60","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1080\/10799893.2016.1203942","volume":"37","author":"S Zhang","year":"2017","unstructured":"Zhang S, Shi L, Ma H, Li H, Li Y, Lu Y, et al. Dihydroartemisinin induces apoptosis in human gastric cancer cell line BGC-823 through activation of JNK1\/2 and p38 MAPK signaling pathways. J Recept Signal Transduct Res. 2017;37(2):174\u201380.","journal-title":"J Recept Signal Transduct Res"},{"issue":"6","key":"3374_CR61","doi-asserted-by":"crossref","first-page":"448","DOI":"10.14348\/molcells.2019.2395","volume":"42","author":"MY Kim","year":"2019","unstructured":"Kim MY, Kruger AJ, Jeong JY, Kim J, Shin PK, Kim SY, et al. Combination Therapy with a PI3K\/mTOR Dual Inhibitor and Chloroquine Enhances Synergistic Apoptotic Cell Death in Epstein-Barr Virus-Infected Gastric Cancer Cells. Mol Cells. 2019;42(6):448\u201359.","journal-title":"Mol Cells"},{"issue":"9","key":"3374_CR62","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.biopha.2010.08.008","volume":"64","author":"X Chao","year":"2010","unstructured":"Chao X, Zao J, Xiao-Yi G, Li-Jun M, Tao S. Blocking of PI3K\/AKT induces apoptosis by its effect on NF-\u03baB activity in gastric carcinoma cell line SGC7901. Biomed Pharmacother. 2010;64(9):600\u20134.","journal-title":"Biomed Pharmacother"},{"issue":"1","key":"3374_CR63","doi-asserted-by":"publisher","first-page":"16017","DOI":"10.1038\/s41598-023-40612-9","volume":"13","author":"S Fukuoka","year":"2023","unstructured":"Fukuoka S, Koga Y, Yamauchi M, Koganemaru S, Yasunaga M, Shitara K, et al. p70S6K\/Akt dual inhibitor DIACC3010 is efficacious in preclinical models of gastric cancer alone and in combination with trastuzumab. Sci Rep. 2023;13(1):16017.","journal-title":"Sci Rep"},{"key":"3374_CR64","doi-asserted-by":"crossref","unstructured":"Lee HJ, Venkatarame Gowda Saralamma V, Kim SM, Ha SE, Raha S, Lee WS et al. Pectolinarigenin induced cell cycle arrest, autophagy, and apoptosis in gastric cancer cell via PI3K\/AKT\/mTOR signaling pathway. Nutrients. 2018;10(8):1043.","DOI":"10.3390\/nu10081043"},{"key":"3374_CR65","doi-asserted-by":"crossref","unstructured":"Wu YJ, Lin SH, Din ZH, Su JH, Liu CI. Sinulariolide inhibits gastric cancer cell migration and invasion through downregulation of the EMT process and suppression of FAK\/PI3K\/AKT\/mTOR and MAPKs signaling pathways. Mar Drugs. 2019;17(12):668.","DOI":"10.3390\/md17120668"},{"issue":"3","key":"3374_CR66","doi-asserted-by":"crossref","first-page":"6332","DOI":"10.1080\/21655979.2021.2005988","volume":"13","author":"F Gao","year":"2022","unstructured":"Gao F, Li R, Wei PF, Ou L, Li M, Bai Y, et al. Synergistic anticancer effects of everolimus (RAD001) and Rhein on gastric cancer cells via phosphoinositide-3-kinase (PI3K)\/protein kinase B (AKT)\/mammalian target of rapamycin (mTOR) pathway. Bioengineered. 2022;13(3):6332\u201342.","journal-title":"Bioengineered"},{"key":"3374_CR67","doi-asserted-by":"crossref","first-page":"175883592412849","DOI":"10.1177\/17588359241284911","volume":"16","author":"AJ Ouissam","year":"2024","unstructured":"Ouissam AJ, Hind C, Sami Aziz B, Said A. Inhibition of the PI3K\/AKT\/mTOR pathway in pancreatic cancer: is it a worthwhile endeavor? Ther Adv Med Oncol. 2024;16:17588359241284911.","journal-title":"Ther Adv Med Oncol"},{"key":"3374_CR68","doi-asserted-by":"crossref","unstructured":"Stanciu S, Ionita-Radu F, Stefani C, Miricescu D, Stanescu S, II, Greabu M et al. Targeting PI3K\/AKT\/mTOR signaling pathway in pancreatic cancer: from molecular to clinical aspects. Int J Mol Sci. 2022;23(17):10132.","DOI":"10.3390\/ijms231710132"},{"key":"3374_CR69","doi-asserted-by":"crossref","unstructured":"Morgos DT, Stefani C, Miricescu D, Greabu M, Stanciu S, Nica S et al. Targeting PI3K\/AKT\/mTOR and MAPK signaling pathways in gastric cancer. Int J Mol Sci. 2024;25(3):1848.","DOI":"10.3390\/ijms25031848"},{"key":"3374_CR70","doi-asserted-by":"crossref","unstructured":"Tian LY, Smit DJ, J\u00fccker M. The Role of PI3K\/AKT\/mTOR Signaling in hepatocellular carcinoma metabolism. Int J Mol Sci. 2023;24(3):2652.","DOI":"10.3390\/ijms24032652"},{"issue":"11","key":"3374_CR71","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1200\/JCO.2009.26.2923","volume":"28","author":"T Doi","year":"2010","unstructured":"Doi T, Muro K, Boku N, Yamada Y, Nishina T, Takiuchi H, et al. Multicenter phase II study of everolimus in patients with previously treated metastatic gastric cancer. J Clin Oncol. 2010;28(11):1904\u201310.","journal-title":"J Clin Oncol"},{"issue":"31","key":"3374_CR72","doi-asserted-by":"crossref","first-page":"3935","DOI":"10.1200\/JCO.2012.48.3552","volume":"31","author":"A Ohtsu","year":"2013","unstructured":"Ohtsu A, Ajani JA, Bai YX, Bang YJ, Chung HC, Pan HM, et al. Everolimus for previously treated advanced gastric cancer: results of the randomized, double-blind, phase III GRANITE-1 study. J Clin Oncol. 2013;31(31):3935\u201343.","journal-title":"J Clin Oncol"},{"issue":"2","key":"3374_CR73","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1159\/000362671","volume":"87","author":"YC Shen","year":"2014","unstructured":"Shen YC, Li CP, Yen CJ, Hsu C, Lin YL, Lin ZZ, et al. Phase II multicentered study of low-dose everolimus plus cisplatin and weekly 24-hour infusion of high-dose 5-fluorouracil and leucovorin as first-line treatment for patients with advanced gastric cancer. Oncology. 2014;87(2):104\u201313.","journal-title":"Oncology"},{"key":"3374_CR74","doi-asserted-by":"crossref","first-page":"145190","DOI":"10.1016\/j.gene.2020.145190","volume":"769","author":"W Zheng","year":"2021","unstructured":"Zheng W, Wu C, Wu X, Cai Y, Liu B, Wang C. Genetic variants of autophagy-related genes in the PI3K\/Akt\/mTOR pathway and risk of gastric cancer in the Chinese population. Gene. 2021;769:145190.","journal-title":"Gene"},{"issue":"13","key":"3374_CR75","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1002\/cncr.29363","volume":"121","author":"RK Ramanathan","year":"2015","unstructured":"Ramanathan RK, McDonough SL, Kennecke HF, Iqbal S, Baranda JC, Seery TE, et al. Phase 2 study of MK-2206, an allosteric inhibitor of AKT, as second-line therapy for advanced gastric and gastroesophageal junction cancer: A SWOG cooperative group trial (S1005). Cancer. 2015;121(13):2193\u20137.","journal-title":"Cancer"},{"key":"3374_CR76","doi-asserted-by":"crossref","first-page":"119984","DOI":"10.1016\/j.lfs.2021.119984","volume":"285","author":"M Akbarzadeh","year":"2021","unstructured":"Akbarzadeh M, Mihanfar A, Akbarzadeh S, Yousefi B, Majidinia M. Crosstalk between miRNA and PI3K\/AKT\/mTOR signaling pathway in cancer. Life Sci. 2021;285:119984.","journal-title":"Life Sci"},{"key":"3374_CR77","doi-asserted-by":"crossref","unstructured":"Ratti S, Mauro R, Rocchi C, Mongiorgi S, Ramazzotti G, Gargiulo M et al. Roles of PI3K\/AKT\/mTOR axis in arteriovenous fistula. Biomolecules. 2022;12(3):350.","DOI":"10.3390\/biom12030350"},{"key":"3374_CR78","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.2147\/OTT.S240803","volume":"13","author":"Q Zhu","year":"2020","unstructured":"Zhu Q, Guo Y, Chen S, Fu D, Li Y, Li Z, et al. Irinotecan Induces Autophagy-Dependent Apoptosis and Positively Regulates ROS-Related JNK- and P38-MAPK Pathways in Gastric Cancer Cells. Onco Targets Ther. 2020;13:2807\u201317.","journal-title":"Onco Targets Ther"},{"issue":"14","key":"3374_CR79","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1158\/1078-0432.CCR-13-0027","volume":"19","author":"K Ng","year":"2013","unstructured":"Ng K, Tabernero J, Hwang J, Bajetta E, Sharma S, Del Prete SA, et al. Phase II study of everolimus in patients with metastatic colorectal adenocarcinoma previously treated with bevacizumab-, fluoropyrimidine-, oxaliplatin-, and irinotecan-based regimens. Clin Cancer Res. 2013;19(14):3987\u201395.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3374_CR80","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1200\/JCO.2008.18.9514","volume":"27","author":"BM Wolpin","year":"2009","unstructured":"Wolpin BM, Hezel AF, Abrams T, Blaszkowsky LS, Meyerhardt JA, Chan JA, et al. Oral mTOR inhibitor everolimus in patients with gemcitabine-refractory metastatic pancreatic cancer. J Clin Oncol. 2009;27(2):193\u20138.","journal-title":"J Clin Oncol"},{"key":"3374_CR81","doi-asserted-by":"crossref","unstructured":"Lee KW, Kim SH, Yoon KC, Lee JM, Cho JH, Hong SK et al. Sirolimus prolongs survival after living donor liver transplantation for hepatocellular carcinoma beyond milan criteria: a prospective, randomised, open-label, multicentre phase 2 trial. J Clin Med. 2020;9(10):3264.","DOI":"10.3390\/jcm9103264"},{"issue":"6","key":"3374_CR82","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1159\/000518297","volume":"10","author":"RK Kelley","year":"2021","unstructured":"Kelley RK, Joseph NM, Nimeiri HS, Hwang J, Kulik LM, Ngo Z, et al. Phase II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma with Tumor Mutation Profiling. Liver Cancer. 2021;10(6):561\u201371.","journal-title":"Liver Cancer"},{"issue":"4","key":"3374_CR83","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s00280-020-04038-8","volume":"85","author":"AW Tolcher","year":"2020","unstructured":"Tolcher AW, Kurzrock R, Valero V, Gonzalez R, Heist RS, Tan AR, et al. Phase I dose-escalation trial of the oral AKT inhibitor uprosertib in combination with the oral MEK1\/MEK2 inhibitor trametinib in patients with solid tumors. Cancer Chemother Pharmacol. 2020;85(4):673\u201383.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"1","key":"3374_CR84","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/01.coc.0000251235.46149.43","volume":"30","author":"W Marsh Rde","year":"2007","unstructured":"Marsh Rde W, Rocha Lima CM, Levy DE, Mitchell EP, Rowland KM Jr., Benson AB. A phase II trial of perifosine in locally advanced, unresectable, or metastatic pancreatic adenocarcinoma. Am J Clin Oncol. 2007;30(1):26\u201331. 3rd.","journal-title":"Am J Clin Oncol"},{"issue":"8","key":"3374_CR85","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/cncr.33364","volume":"127","author":"ES Tan","year":"2021","unstructured":"Tan ES, Cao B, Kim J, Al-Toubah TE, Mehta R, Centeno BA, et al. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers. Cancer. 2021;127(8):1293\u2013300.","journal-title":"Cancer"},{"key":"3374_CR86","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.ejca.2018.11.017","volume":"108","author":"YJ Bang","year":"2019","unstructured":"Bang YJ, Kang YK, Ng M, Chung HC, Wainberg ZA, Gendreau S, et al. A phase II, randomised study of mFOLFOX6 with or without the Akt inhibitor ipatasertib in patients with locally advanced or metastatic gastric or gastroesophageal junction cancer. Eur J Cancer. 2019;108:17\u201324.","journal-title":"Eur J Cancer"},{"issue":"9","key":"3374_CR87","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1080\/17425255.2019.1663169","volume":"15","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Yan H, Xu Z, Yang B, Luo P, He Q. Molecular basis for class side effects associated with PI3K\/AKT\/mTOR pathway inhibitors. Expert Opin Drug Metab Toxicol. 2019;15(9):767\u201374.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"5","key":"3374_CR88","doi-asserted-by":"crossref","first-page":"653","DOI":"10.3390\/biom16050653","volume":"16","author":"A Keyhani","year":"2026","unstructured":"Keyhani A, Haddad Kashani H, Dizaji Asl K, Mazloumi Z, Kaikavoosnejad F, Ashraf Moosavi SS, et al. Targeting the WNT\/\u03b2-Catenin Pathway in Hematological Malignancies: From Molecular Pathogenesis to Emerging Therapeutic Strategies. Biomolecules. 2026;16(5):653.","journal-title":"Biomolecules"},{"issue":"3","key":"3374_CR89","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ejca.2011.11.028","volume":"48","author":"C Gomez-Fernandez","year":"2012","unstructured":"Gomez-Fernandez C, Garden BC, Wu S, Feldman DR, Lacouture ME. The risk of skin rash and stomatitis with the mammalian target of rapamycin inhibitor temsirolimus: a systematic review of the literature and meta-analysis. Eur J Cancer. 2012;48(3):340\u20136.","journal-title":"Eur J Cancer"},{"issue":"4","key":"3374_CR90","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1634\/theoncologist.2013-0231","volume":"19","author":"X Liu","year":"2014","unstructured":"Liu X, Lorusso P, Mita M, Piha-Paul S, Hong DS, Fu S, et al. Incidence of mucositis in patients treated with temsirolimus-based regimens and correlation to treatment response. Oncologist. 2014;19(4):426\u20138.","journal-title":"Oncologist"},{"issue":"3","key":"3374_CR91","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1093\/annonc\/mdv595","volume":"27","author":"HS Rugo","year":"2016","unstructured":"Rugo HS, Hortobagyi GN, Yao J, Pavel M, Ravaud A, Franz D, et al. Meta-analysis of stomatitis in clinical studies of everolimus: incidence and relationship with efficacy. Ann Oncol. 2016;27(3):519\u201325.","journal-title":"Ann Oncol"},{"key":"3374_CR92","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1146\/annurev-nutr-071714-034355","volume":"35","author":"A Caron","year":"2015","unstructured":"Caron A, Richard D, Laplante M. The Roles of mTOR Complexes in Lipid Metabolism. Annu Rev Nutr. 2015;35:321\u201348.","journal-title":"Annu Rev Nutr"},{"issue":"4","key":"3374_CR93","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/j.cmet.2013.08.002","volume":"18","author":"DW Lamming","year":"2013","unstructured":"Lamming DW, Sabatini DM. A Central role for mTOR in lipid homeostasis. Cell Metab. 2013;18(4):465\u20139.","journal-title":"Cell Metab"},{"key":"3374_CR94","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1017\/S1462399411002109","volume":"14","author":"SM Schultze","year":"2012","unstructured":"Schultze SM, Hemmings BA, Niessen M, Tschopp O. PI3K\/AKT, MAPK and AMPK signalling: protein kinases in glucose homeostasis. Expert Rev Mol Med. 2012;14:e1.","journal-title":"Expert Rev Mol Med"},{"issue":"11","key":"3374_CR95","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1038\/bjc.2015.373","volume":"113","author":"E Geuna","year":"2015","unstructured":"Geuna E, Roda D, Rafii S, Jimenez B, Capelan M, Rihawi K, et al. Complications of hyperglycaemia with PI3K-AKT-mTOR inhibitors in patients with advanced solid tumours on Phase I clinical trials. Br J Cancer. 2015;113(11):1541\u20137.","journal-title":"Br J Cancer"},{"issue":"1","key":"3374_CR96","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ctrv.2013.04.005","volume":"40","author":"S Sivendran","year":"2014","unstructured":"Sivendran S, Agarwal N, Gartrell B, Ying J, Boucher KM, Choueiri TK, et al. Metabolic complications with the use of mTOR inhibitors for cancer therapy. Cancer Treat Rev. 2014;40(1):190\u20136.","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"3374_CR97","doi-asserted-by":"publisher","first-page":"85","DOI":"10.2165\/00002018-200932010-00008","volume":"32","author":"KK Swisher","year":"2009","unstructured":"Swisher KK, Li X, Vesely SK, George JN. Drug-induced thrombocytopenia: an updated systematic review, 2008. Drug Saf. 2009;32(1):85\u20136.","journal-title":"Drug Saf"},{"key":"3374_CR98","doi-asserted-by":"crossref","first-page":"114729","DOI":"10.1016\/j.taap.2019.114729","volume":"381","author":"W Liu","year":"2019","unstructured":"Liu W, Jing ZT, Xue CR, Wu SX, Chen WN, Lin XJ, et al. PI3K\/AKT inhibitors aggravate death receptor-mediated hepatocyte apoptosis and liver injury. Toxicol Appl Pharmacol. 2019;381:114729.","journal-title":"Toxicol Appl Pharmacol"},{"issue":"3","key":"3374_CR99","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/nrclinonc.2013.10","volume":"10","author":"J Rodon","year":"2013","unstructured":"Rodon J, Dienstmann R, Serra V, Tabernero J. Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol. 2013;10(3):143\u201353.","journal-title":"Nat Rev Clin Oncol"},{"issue":"48","key":"3374_CR100","doi-asserted-by":"crossref","first-page":"6111","DOI":"10.3748\/wjg.v16.i48.6111","volume":"16","author":"JW Han","year":"2010","unstructured":"Han JW, Zhan XR, Li XY, Xia B, Wang YY, Zhang J, et al. Impaired PI3K\/Akt signal pathway and hepatocellular injury in high-fat fed rats. World J Gastroenterol. 2010;16(48):6111\u20138.","journal-title":"World J Gastroenterol"},{"key":"3374_CR101","doi-asserted-by":"crossref","unstructured":"Mishra R, Patel H, Alanazi S, Kilroy MK, Garrett JT. PI3K inhibitors in cancer: clinical implications and adverse effects. Int J Mol Sci. 2021;22(7):3464.","DOI":"10.3390\/ijms22073464"},{"issue":"4","key":"3374_CR102","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1158\/2159-8290.CD-18-1175","volume":"9","author":"AB Hanker","year":"2019","unstructured":"Hanker AB, Kaklamani V, Arteaga CL. Challenges for the Clinical Development of PI3K Inhibitors: Strategies to Improve Their Impact in Solid Tumors. Cancer Discov. 2019;9(4):482\u201391.","journal-title":"Cancer Discov"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03374-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03374-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-026-03374-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:42:03Z","timestamp":1792096923000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-026-03374-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,29]]},"references-count":102,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["3374"],"URL":"https:\/\/doi.org\/10.1007\/s12032-026-03374-8","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,29]]},"assertion":[{"value":"3 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"256"}}